Company profile: Cerevance
1.1 - Company Overview
Company description
- Provider of therapeutics for CNS disorders, leveraging its NETSseq platform to identify novel targets. Pipeline includes CVN424, a first-in-class compound targeting a novel receptor with phase 2 efficacy in Parkinson’s disease; CVN766, a selective orexin 1 antagonist for psychiatric conditions focused on avoiding somnolence; and CVN293, a KCNK13 inhibitor under investigation for ALS and Alzheimer’s.
Products and services
- NETSseq Platform: A cell-type-specific technology platform analyzing gene expression in defined brain cell types to identify novel targets for CNS disorder treatments and guide Cerevance’s therapeutic development
- CVN424: A clinical-stage, first-in-class compound targeting a novel receptor for Parkinson’s Disease, demonstrated efficacy in a phase 2 study
- CVN293: A target-selective KCNK13 inhibitor engineered to modulate neuroinflammation, under investigation for therapeutic application in ALS and Alzheimer’s Disease
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cerevance
CereVasc
HQ: United States
Website
- Description: Provider of endovascular medical devices for treating hydrocephalus, including the eShunt System—an endovascularly implantable cerebrospinal fluid shunt with delivery components designed to treat communicating hydrocephalus without invasive surgery—and a portfolio of follow-on product concepts to improve care for neurovascular diseases, including therapies deliverable across the blood-brain barrier.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CereVasc company profile →
Rapid Dose Therapeutics
HQ: Canada
Website
- Description: Provider of pharma-tech oral fast-dissolving drug delivery solutions, including QuickStrip for direct bloodstream delivery of pharmaceuticals and over-the-counter medicines; RDMx + QuickStrip for enabling delivery of large therapeutic molecules; Rapid Energy, Vitamin B12, and Melatonin QuickStrip products; and versions for elderly and pediatric patients needing simplified, rapid dosing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rapid Dose Therapeutics company profile →
Sonoma Bio
HQ: United States
Website
- Description: Provider of Treg and Teff cell therapies and autoimmune disease research, developing adoptive Treg therapies for rheumatoid arthritis, inflammatory bowel disease, and hidradenitis suppurativa. Pipeline includes SBT-77-7101, a Treg cell therapy targeting citrullinated proteins to reduce inflammation, and SBT-11-5301, a Phase 1 effector T cell-modulating biologic, with clinical trials assessing safety and effectiveness.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sonoma Bio company profile →
Diagnamed
HQ: Canada
Website
- Description: Provider of digital health AI platforms and tools to improve brain health, including BRAIN AGE AI for estimating brain age and assessing cognitive decline using EEG and machine learning; CERVAI Brain Health AI for assessments and research with generative AI; Dr. GenAI, a healthcare chatbot; PalGPT.ai for brain health applications; and FormGPT.io for healthcare applications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Diagnamed company profile →
Remedy Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage small molecule drug therapies for acute central nervous system disorders, developing treatments that target NCCa-ATP channels in traumatic brain injury, stroke, and spinal cord injury, including RP-1127, an intravenous glyburide inhibitor acting through type-1 sulfonylurea antagonism.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Remedy Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cerevance
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cerevance
2.2 - Growth funds investing in similar companies to Cerevance
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cerevance
4.2 - Public trading comparable groups for Cerevance
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →